MedPath

Reducing Blood Loss During Cesarean Section by Topical Versus IV Tranexamic Acid

Not Applicable
Completed
Conditions
Cesarean Section Complications
Interventions
Drug: Topical tranexamic acid
Drug: intravenous tranexamic acid
Other: normal saline arm group
Registration Number
NCT03706339
Lead Sponsor
Aswan University Hospital
Brief Summary

Tranexamic (TXA)acid is an inexpensive, antifibrinolytic drug long used to control bleeding due to surgery, menorrhagia, or trauma. Additionally, tranexamic acid has been shown to reduce bleeding during cesarean delivery as well as the need for additional uterotonic agents, albeit to a minimal degree. However, previous studies have been performed only in women with a standard risk for postpartum hemorrhage( PPH) and have not focused on assessing the effects of tranexamic acid in high-risk women. The aim of this study is to evaluate the efficacy of IV versus topical application of tranexamic acid in reducing blood loss during and after elective C.S. The Research Question Is topical application of Tranexamic acid effective in reducing blood loss during and after an elective Caesarean section? The Research Hypothesis the TXA could be able to reduce blood loss during and after elective Caesarean section. The null hypothesis will, therefore, state that: There will be no difference between topical and IV TXA and placebo in reducing blood loss during and after elective Caesarean section.

Detailed Description

patients were allocated to one of three groups after induction of general anesthesia and immediately prior to the operation and just before skin incision. they received 1-gram tranexamic acid (10 ml) in 100 ml saline infusion or placebo (110 normal saline) by slow intravenous injection at an approximate rate of 1 mL per min. Throughout the operation, irrigation was done by 60 ml of (2g tranexamic acid (10 ml) diluted in 100 ml of sodium chloride 0.9%) or placebo ( 60 ml of sodium chloride 0.9%.).At the end of operation, another dose of 60 ml of (1g tranexamic acid (10 ml) diluted in 50 ml of sodium chloride 0.9%) or placebo ( 60 ml of sodium chloride 0.9%.) was left intraabdominal

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
450
Inclusion Criteria
  • all pregnant women with a single term fetus scheduled for elective cesarean section who will be at risk of postpartum hemorrhage
Exclusion Criteria
  • Patients with a cardiac, hepatic, renal or thromboembolic disease. ,
  • patients with the high possibility of the morbid adherent placenta,
  • known coagulopathy and
  • those presented with severe antepartum hemorrhage
  • refuse to participate

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Topical tranexamic acid groupTopical tranexamic acid2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 100 ml normal saline applied on the placental bed after Cesarean section plus110 ml normal saline IV just before skin incision
intravenous tranexamic acid groupintravenous tranexamic acid1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus100 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
normal saline arm groupnormal saline arm groupthey received 110 ml saline infusion or placebo (110 normal salines) by slow intravenous injection at an approximate rate of 1 mL per min plus Throughout the operation irrigation was done by120 ml saline
Primary Outcome Measures
NameTimeMethod
intraoperative blood lossduring the operation

measures the intraoperative blood loss by direct and gravimetric methods

Secondary Outcome Measures
NameTimeMethod
postoperative blood loss24 hours postoperative

measurement the intraoperative blood loss by direct and gravimetric methods

need of blood transfusion24 hours postoperative

number of unites of blood transfusion

need of uterotonicduring operation

misoprostol,oxytocin etc

change in hemoglobinBaseline and 24 hours postoperative

Trial Locations

Locations (1)

Aswan University

🇪🇬

Aswan, Egypt

© Copyright 2025. All Rights Reserved by MedPath